Midatech Pharma Signs Licensing Pact With Novartis

Features Dow Jones Newswires

Pharmaceutical company Midatech Pharma PLC (MTPH.LN) said Wednesday that it has signed a global licensing agreement with Novartis AG (NOVN.EB) for the oncology compound panobinostat.

Continue Reading Below

The company intends to develop panobinostat for the treatment of brain tumor.

Shares at 0741 GMT trading 4.4% higher at 108 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

June 07, 2017 03:59 ET (07:59 GMT)